They studied three groups of patients: those who were cancer - free, those diagnosed with
precancerous cystic lesions, and patients with pancreatic cancer.
First author Michele T. Yip - Schneider, Ph.D., associate research professor of surgery, and senior author C. Max Schmidt, M.D., Ph.D., MBA, professor of surgery, biochemistry and molecular biology, report this is the first cyst fluid protein biomarker that can differentiate serous cystic neoplasms, a benign type of cystic lesion, from all other cancerous or
precancerous cystic lesions without surgery.